New CBER Panel Should Be Established For Combo Products Review – AAOS
This article was originally published in The Gray Sheet
Executive Summary
A new FDA advisory panel under the purview of the Center for Biologics Evaluation & Research should be created specifically to review combination products, the American Academy of Orthopaedic Surgeons recommends
You may also be interested in...
FDA Will Accept Primary Mode Of Action Definition Comments Until Jan. 24
Clarification of primary mode of action (PMOA) is a priority for the soon-to-be established Office of Combination Products, according to Mark Kramer, director of the agency's current combination product program within the FDA Office of the Ombudsman
Wyeth BMP-2 Should Be Limited To “Problem” Fractures – Panel
Wyeth's InductOs recombinant human bone morphogenic protein-2 indications for use should be limited to "problem" fractures, according to FDA's Orthopaedic and Rehabilitation Devices Panel
Medical Imaging Drugs Advisory Committee Will Phase Out By March 2004
FDA's Medical Imaging Drugs and Pharmacy Compounding advisory committees will terminate after their charters expire in February 2004